Published in Antimicrob Agents Chemother on August 17, 2015
Population Pharmacokinetic Modeling of Tenofovir in the Male Genital Tract of HIV-infected Patients. Antimicrob Agents Chemother (2016) 0.75
Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates. PLoS One (2016) 0.75
Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med (2000) 41.18
Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS (2009) 11.62
Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med (2011) 6.79
Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. The Swiss HIV Cohort Study. AIDS (2000) 4.91
Persistent HIV RNA shedding in semen despite effective antiretroviral therapy. AIDS (2009) 2.77
Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection. AIDS Res Hum Retroviruses (2004) 2.04
Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers. J Clin Pharmacol (2007) 2.03
Highly active antiretroviral therapy does not completely suppress HIV in semen of sexually active HIV-infected men who have sex with men. AIDS (2012) 1.56
Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract. Antivir Ther (2011) 1.33
Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma on a 2002-2011 survey. AIDS (2012) 1.27
Semen may harbor HIV despite effective HAART: another piece in the puzzle. PLoS One (2010) 1.16
Relationship between HIV-RNA load in blood and semen in antiretroviral-naïve and experienced men and effect of asymptomatic sexually transmissible infections. Curr HIV Res (2008) 1.07
Differential extracellular and intracellular concentrations of zidovudine and lamivudine in semen and plasma of HIV-1-infected men. J Acquir Immune Defic Syndr (2008) 1.02
Antiretroviral drug concentrations in the male and female genital tract: implications for the sexual transmission of HIV. Curr Opin HIV AIDS (2010) 1.01
Origins of HIV-infected leukocytes and virions in semen. J Infect Dis (2014) 1.00
Expression of ATP-binding cassette membrane transporters in rodent and human sertoli cells: relevance to the permeability of antiretroviral therapy at the blood-testis barrier. J Pharmacol Exp Ther (2011) 1.00
HIV-1 DNA levels in peripheral blood mononuclear cells and cannabis use are associated with intermittent HIV shedding in semen of men who have sex with men on successful antiretroviral regimens. Clin Infect Dis (2014) 0.99
Pharmacokinetic evaluation of emtricitabine in combination with other nucleoside antivirals in healthy volunteers. J Clin Pharmacol (2007) 0.99
Understanding HIV compartments and reservoirs. Curr HIV/AIDS Rep (2014) 0.95
Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal women. Clin Pharmacokinet (2012) 0.91
Population pharmacokinetics of emtricitabine in HIV-1-infected adult patients. Antimicrob Agents Chemother (2014) 0.89
Emtricitabine: Inhibitor and substrate of multidrug resistance associated protein. Eur J Pharm Sci (2008) 0.82
Correlation between HIV-1 RNA load in blood and seminal plasma depending on antiretroviral treatment status, regimen and penetration of semen by antiretroviral drugs. Curr HIV Res (2008) 0.81
Renal excretion of emtricitabine I: effects of organic anion, organic cation, and nucleoside transport inhibitors on emtricitabine excretion. J Pharm Sci (2008) 0.80
Population Pharmacokinetic Modeling of Tenofovir in the Male Genital Tract of HIV-infected Patients. Antimicrob Agents Chemother (2016) 0.75